Username Password
S&P 500: 1,159.90 Change: -0.51%

DENDREON CORPORATION (DNDN)

Overview
Price $35.03
Price change for today in $ $-1.13
Price change for today in % -3.13%
P&P rating Rating: 3
Open Price $28.20
Previous close $36.16
Daily Range
52-Week Range $4.02 - $37.09
Volume 0
chart
Rate this Stock!
You haven't rated this stock yet!

What The Community Thinks

Total Players

171 Buy
18 Sell
 
Top Buy Analysis
BUY: DNDN Rating: 3
Company: DENDREON CORPORATION
Points: 68.34
Start Price: $16.99
Start Date: 04/14/2009 10:18 AM
MightyMo
MightyMo
P&P Score: 99.85
Recs:
Positive cancer study data

Comments: 0 | Comment


Top Sell Analysis
SELL: DNDN Rating: 3
Company: DENDREON CORPORATION
Points: 2.63
Start Price: $35.30
Start Date: 03/05/2010 1:01 PM
Nomadamon
Nomadamon
P&P Score: 98.92
Recs:
It has gotten ahead of itself on good news about Provenge. May go up some more first but it will return to a more reasonable price point soon.

Comments: 0 | Comment

Picks
Username P&P Score Call Time Frame Start Date Start Price Today (change) Stock Gain S&P Gain Points Analysis
mkittels 98.09 BUY One to Three Months 03/17/2010 $36.16 $35.03
(-3.13%)
-3.13% -0.51% -2.62 view
lowtolerance 99.95 BUY Week or Less 03/08/2010 $35.43 $35.03
(-3.13%)
-1.13% +1.88% -3.01
jandonieh BUY Six Months to a Year 03/07/2010 $35.30 $35.03
(-3.13%)
-0.76% +1.86% -2.63 view
Nomadamon 98.92 SELL One to Three Months 03/05/2010 $35.30 $35.03
(-3.13%)
-0.76% +1.86% +2.63 view
Kenneth_Jezewski 3.17 BUY Week to a Month 03/05/2010 $35.30 $35.03
(-3.13%)
-0.76% +1.86% -2.63 view
JoeCole 89.47 SELL Three to Six Months 03/04/2010 $34.85 $35.03
(-3.13%)
+0.52% +3.29% +2.77 view
seagate5 BUY Three to Six Months 03/03/2010 $34.85 $35.03
(-3.13%)
+0.52% +3.29% -2.77 view
Yade 97.60 BUY One to Three Months 02/01/2010 $29.22 $35.03
(-3.13%)
+19.88% +6.49% +13.39 view
ak3583 71.70 BUY One to Three Years 01/27/2010 $28.20 $35.03
(-3.13%)
+24.22% +5.69% +18.53
HugeGains83 98.83 BUY One to Three Years 11/28/2009 $27.24 $35.03
(-3.13%)
+28.60% +6.27% +22.33 view
Pages: [ 1 ]  2   3   4   5   ...  19  >>
Commentary
BUY: DENDREON CORPORATION (DNDN) Rating: 3
Start Price: $36.16
Points: -2.62
Created: 03/17/2010
Nice movement of late.

Comments: 0 | Comment

Recs:
 
BUY: DENDREON CORPORATION (DNDN) Rating: 3
Start Price: $35.30
Points: -2.63
Created: 03/07/2010
It has shown many strength,

Comments: 0 | Comment

Recs:
 
SELL: DENDREON CORPORATION (DNDN) Rating: 3
Start Price: $35.30
Points: +2.63
Created: 03/05/2010
It has gotten ahead of itself on good news about Provenge. May go up some more first but it will return to a more reasonable price point soon.

Comments: 0 | Comment

Recs:
 
BUY: DENDREON CORPORATION (DNDN) Rating: 3
Start Price: $35.30
Points: -2.63
Created: 03/05/2010
good gainer

Comments: 0 | Comment

Recs:
 
SELL: DENDREON CORPORATION (DNDN) Rating: 3
Start Price: $34.85
Points: +2.77
Created: 03/04/2010
Even if provenge is a success, you still have a one trick overpriced pony

Comments: 0 | Comment

Recs:
 
BUY: DENDREON CORPORATION (DNDN) Rating: 3
Start Price: $34.85
Points: -2.77
Created: 03/03/2010
I picked up this stock in the fall, 2009 when it was @ $9.00. I sold it at $23 last year, despite listening to a guy tell me back then it was going to settle in at +/- $40.00, in the spring.

Originally, my order was scheduled to go in @ $5, but (my luck) DNDN stopped trading for almost 3 hours, due to 'trader irregularities!' The original order did not go through. Had the stock tanked, no doubt it would have gone through.

I again picked up DNDN at $28. At $25, DNDN seemed to receive increased daily volume and options action. Now that it has moved past $30 and has held there, I believe the guy who said it would reach $40, either was lucky or really knew, It may take awhile, but if the drug they are producing (a prostate cancer retardant?), receives FDA approval, it will zoom past $60 almost overnight.

I am not a 'WOW' person, but this may be as close as it gets.

Comments: 0 | Comment

Recs:
 
BUY: DENDREON CORPORATION (DNDN) Rating: 3
Start Price: $29.22
Points: +13.39
Created: 02/01/2010
Dendreon has released data from a subsequent trial that shows it met its primary end point for the trial, giving bulls their way and driving the stock to $30 and change - it is now around $28. The company is expecting an FDA decision - and approval - on or near May 1. Analysts peg Provenge sales at around one billion by 2018. The puts the current market cap is $3.25 billion.

Comments: 0 | Comment

Recs:
 
BUY: DENDREON CORPORATION (DNDN) Rating: 3
Start Price: $27.24
Points: +22.33
Created: 11/28/2009
huge cancer therapy very positive

Comments: 0 | Comment

Recs:
 
BUY: DENDREON CORPORATION (DNDN) Rating: 3
Start Price: $24.27
Points: +26.79
Created: 07/29/2009
DNDN is working to get everything that FDA will require to have their prostate drug approved. Before they ask for drug certification dndn will have the cash,factory and employees ready to start production..

Comments: 0 | Comment

Recs:
 
BUY: DENDREON CORPORATION (DNDN) Rating: 3
Start Price: $23.42
Points: +26.55
Created: 05/30/2009
Easy double or even triple.New prostate cancer drug has2-3 billion $ per year sales potential.Also company maybe takeover target for big pharma cos.

Comments: 0 | Comment

Recs:
 
Pages: [ 1 ]  2   3   4   5   ...  19  >>
Sponsored Links